RecruitingPhase 1NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Elranatamab(drug)
- Enrollment
- 87 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables, Florida, United States
- University of Miami Hospital and Clinics Deerfield Beach, Deerfield Beach, Florida, United States
- Sylvester Comprehensive Cancer Center- Doral, Doral, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- University of Miami Hospital and Clinics, Miami, Florida, United States
- Sylvester Comprehensive Cancer Center Kendall, Miami, Florida, United States
- Sylvester Comprehensive Cancer Center Plantation, Plantation, Florida, United States
- Emory University Hospital Midtown, Atlanta, Georgia, United States
- Emory University Hospital, Atlanta, Georgia, United States
- Winship Cancer Institute, Atlanta, Georgia, United States
- Indiana CTSI Clinical Research Center (ICRC), Indianapolis, Indiana, United States
- Indiana University Health University Hospital, Indianapolis, Indiana, United States
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC), Indianapolis, Indiana, United States
- University of Maryland, Baltimore, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06215118 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.
- RECRUITINGNANCT07359014Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaSecond Affiliated Hospital, School of Medicine, Zhejiang University